MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Ticker SymbolMDXG
Company nameMiMedx Group Inc
IPO dateAug 20, 2007
CEOCapper (Joseph H)
Number of employees837
Security typeOrdinary Share
Fiscal year-endAug 20
Address1775 W Oak Commons Court, Ne
CityMARIETTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30062
Phone17706519100
Websitehttps://mimedx.com/
Ticker SymbolMDXG
IPO dateAug 20, 2007
CEOCapper (Joseph H)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data